Sunshine Biopharma, Inc.
NASDAQ Capital MarketTotal Valuation
Sunshine Biopharma, Inc. carries a market capitalization of 2.71M, placing it among publicly traded companies globally. Its enterprise value stands at -8.06M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.71M |
| Enterprise Value | -8.06M |
Share Statistics
Sunshine Biopharma, Inc. currently has 2.38M shares outstanding.
| Shares Outstanding | 2.38M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.05, and the price-to-book ratio stands at 0.18.
| PE Ratio | N/A |
| PS Ratio | 0.05 |
| PB Ratio | 0.18 |
| P/TBV Ratio | 0.19 |
| P/FCF Ratio | -0.31 |
| P/OCF Ratio | -0.30 |
Enterprise Valuation
| EV / Sales | 2.86 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Sunshine Biopharma, Inc. maintains a current ratio of 5.46, meaning it holds 5.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.46 |
| Quick Ratio | 3.16 |
| Debt / Equity | 2.46 |
| Debt / EBITDA | -0.14 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -21.93 |
| Return on Assets (ROA) | -17.78 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.96 |
Taxes
| Income Tax | 270,936.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Sunshine Biopharma, Inc.'s stock has declined approximately -91.91489% over the past 52 weeks. The 50-day moving average sits at 1.51, while the 200-day moving average is 8.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | -91.91489% |
| 50-Day Moving Average | 1.51 |
| 200-Day Moving Average | 8.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Sunshine Biopharma, Inc. generated 35.35M in revenue and converted that into -5.83M in net income, yielding earnings per share of -7.57. EBITDA reached -4.85M, while operating income came in at -5.20M.
| Revenue | 35.35M |
| Gross Profit | 10.71M |
| Operating Income | -5.20M |
| Pretax Income | -5.56M |
| Net Income | -5.83M |
| EBITDA | -4.85M |
| EBIT | -5.20M |
| Earnings Per Share (EPS) | -7.57 |
Balance Sheet
Sunshine Biopharma, Inc. holds 13.75M in cash and equivalents against 678,338.00 in total debt, resulting in a net debt position of -13.75M. Total book value stands at 27.53M, with working capital of 25.05M providing operational flexibility.
| Cash & Cash Equivalents | 13.75M |
| Total Debt | 678,338.00 |
| Net Debt | -13.75M |
| Equity (Book Value) | 27.53M |
| Book Value Per Share | 11.57 |
| Working Capital | 25.05M |
Cash Flow
Sunshine Biopharma, Inc. produced -5.35M in operating cash flow over the past twelve months. After subtracting -183,740.00 in capital expenditures, free cash flow totaled -5.54M - equivalent to -7.19 per share.
| Operating Cash Flow | -5.35M |
| Capital Expenditures | -183,740.00 |
| Free Cash Flow | -5.54M |
| FCF Per Share | -7.19 |
Margins
Sunshine Biopharma, Inc. operates with a gross margin of 30.30, reflecting its pricing power and cost economics. The operating margin of -14.71 and net profit margin of -16.50 provide insight into operational efficiency.
| Gross Margin | 30.30 |
| Operating Margin | -14.71 |
| Pretax Margin | -15.73 |
| Profit Margin | -16.50 |
| EBITDA Margin | -13.72 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -170.76 |
| FCF Yield | -319.46 |
Stock Splits
Sunshine Biopharma, Inc.'s most recent stock split took place on June 1, 2026 with a 10:1 split ratio.
| Last Split Date | 6/1/2026 |
| Split Ratio | 10:1 |
Scores
Sunshine Biopharma, Inc. posts an Altman Z-Score of -1.42, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.42 |